Telos Capital Management Inc Q3 2026 Portfolio Shifts: Focus on Healthcare and Technology
Telos Capital Management's institutional filing reveals significant changes in holdings during the third quarter of 2026, highlighting both strategic purchases and sales across various sectors.
According to the latest filing from Telos Capital Management Inc, institutional investors made notable adjustments to their portfolio during Q3 2026. The data shows a mix of buying and selling activities, with specific emphasis on certain sectors and individual stocks.
Key among the purchases was XLV (SELECT SECTOR SPDR TR). This exchange-traded fund represents a substantial new investment in broad-based healthcare exposure, jumping from zero shares to its current allocation. The filing indicates that this position was initiated entirely during the quarter.
In the Technology sector, two significant buys were observed: N6596X109 (NXP SEMICONDUCTORS N V) and KLAC (KLA CORP). The stake in N6596X109 increased by nearly 21% during Q3, while KLAC saw an extraordinary increase of over 892%, suggesting strong confidence or a strategic allocation into these specific tech companies.
Conversely, the investor significantly reduced exposure to certain areas. TROW (PRICE T ROWE GROUP), another Financial Services holding, experienced one of the most drastic reductions in this filing, with over 75% of its stake sold off during Q3.
The Technology sector also saw notable selling pressure on NVDA (NVIDIA CORPORATION). The position was trimmed by approximately 26.74%, indicating a strategic reduction or realignment away from high-growth AI stocks, despite their strong performance.
Additionally, the filing shows activity in index funds and ETFs like VCSH and IGV, which were increased during Q3, while others like SCHD saw reductions. These movements suggest ongoing tactical adjustments within specific asset classes or strategies.